Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.42 |
| ▸ | EPOR | P19235 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787391 | 1.00 | GSR (0.46) | GSRRNPEPCPB2EPORFOLH1 | |
| SCHEMBL29067246 | 0.83 | GRIK1 (0.41) | GSRRNPEPCPB2GRIK1GRIK2 | |
| SCHEMBL4298060 | 0.81 | GSR (0.48) | GSRRNPEPCPB2EPORFOLH1 | |
| SCHEMBL4298056 | 0.81 | GSR (0.48) | GSRRNPEPCPB2EPORFOLH1 | |
| SCHEMBL11013496 | 0.81 | SLC6A5 (0.43) | GSRRNPEPCPB2GRIK1GRIK2 | |
| SCHEMBL28509039 | 0.80 | GSR (0.47) | GSRRNPEPCPB2FOLH1GABRR1 | |
| SCHEMBL6267879 | 0.80 | GSR (0.47) | GSRRNPEPCPB2FOLH1GABRR1 | |
| SCHEMBL2725758 | 0.78 | GSR (0.48) | GSRRNPEPCPB2EPORFOLH1 | |
| SCHEMBL634033 | 0.78 | GSR (0.48) | GSRRNPEPCPB2EPORFOLH1 | |
| SCHEMBL6739029 | 0.77 | CPB2 (0.45) | GSRRNPEPCPB2FOLH1GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025560-A1 | METHOD FOR THE REVIVAL OF MICROGLIA AND ASTROCYTES AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTH CAROLINA | 2025-01-23 | — | — | US | claimed |
| US-20250025560-A1 | METHOD FOR THE REVIVAL OF MICROGLIA AND ASTROCYTES AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTH CAROLINA | 2025-01-23 | — | — | US | disclosed |
| CN-114847317-B | Method for simultaneously reducing the content of 4-methylimidazole and advanced glycation end products in bakery products based on natural active ingredients | 江南大学 | 2023-08-11 | — | — | CN | disclosed |
| CN-114847317-A | Method for simultaneously reducing the content of 4-methylimidazole and advanced glycation end products in bakery products based on natural active ingredients | 江南大学 | 2022-08-05 | — | — | CN | disclosed |
| WO-2008029162-A1 | BIOMARKERS | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2008-03-13 | — | — | WO | disclosed |
| EP-1272843-B1 | METHOD FOR IDENTIFYING REGULATORS OF PROTEIN-AGE FORMATION | NIADYNE CORP (US) | 2007-06-20 | — | — | EP | disclosed |
| US-6716635-B2 | MIXING A SUBSTANCE TO BE TESTED, A HISTONE H1 AND ADP-RIBOSE AND MEASURING THE FLUORESCENCE AND PROTEIN CROSSLINKING; COMBINATORIAL LIBRARIES; ANTIDIABETIC AGENTS; ATHEROSCLEROSIS, CHRONIC NEURODEGENERATIVE DISEASES, E.G.,ALZHEIMER'S; | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2004-04-06 | — | — | US | disclosed |
| WO-2003020899-A2 | COMPOSITIONS AND METHODS RELATING TO LUNG SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| EP-1272843-A2 | METHOD FOR IDENTIFYING REGULATORS OF PROTEIN-AGE FORMATION | Niadyne Corporation (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020037496-A1 | Method for identifying regulators of protein-advanced glycation end product (protein-AGE) formation | NIADYNE, INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2001079842-A2 | METHOD FOR IDENTIFYING REGULATORS OF PROTEIN-AGE FORMATION | NIADYNE CORPORATION (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025560-A1 | METHOD FOR THE REVIVAL OF MICROGLIA AND ASTROCYTES AND APPLICATIONS THEREOF | L1CAM, CD274, PDCD1LG2 | GSR 592/4885RNPEP 1788/4885CPB2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.